UC Irvine Researchers Secure NIH Grant to Develop Life-Saving Wearable Patch

Michelle Khine, Amir Rahmani, and Bernard Choi receive federal funding to build a smart, wearable device capable of detecting life-threatening blood loss before it becomes fatal, with a critical focus on real-time monitoring in the operating room.

Drs. Michelle Khine and Bernard Choi of UC Irvine Beckman Laser Institute & Medical Clinic and Dr. Amir Rahmani of the School of Nursing have been awarded a two-year $408,504 grant from the National Institute on Aging to develop a groundbreaking wearable patch that can monitor a patient’s blood flow and detect dangerous bleeding in real time, especially in the operating room on patients at high risk for hemorrhage.

Trauma is one of the leading causes of death worldwide, with a significant portion of those deaths caused by severe bleeding, or hemorrhage. Hemorrhagic shock is especially deadly, as the warning signs are often subtle and go undetected until a patient is already in critical condition.

Current monitoring tools in hospitals, operating rooms, and emergency settings are often bulky, invasive, or unable to catch early warning signs. The problem is compounded by racial disparities in trauma outcomes, where patients may receive delayed or less accurate care, as existing monitoring technologies do not perform equally well across all skin tones.

To address these challenges, Drs. Khine, Rahmani, and Choi are developing a novel, integrated, wearable hemodynamic platform designed for the early detection and management of hemorrhage. The device combines miniaturized sensor technologies, including Micro-Electro-Mechanical Systems (MEMS), laser speckle imaging, and diffuse optical spectroscopy. By integrating these technologies with machine learning algorithms, the patch can continuously monitor vital signs and blood flow, enabling faster and more accurate interventions.

“By developing a wearable technology that monitors vital signs and predicts the risk of bleeding – a preventable factor in many cases – our goal is to make early detection and intervention possible, potentially saving millions of lives,” said Bernard Choi, interim director of the Institute.

The project will advance in three major phases. First, the patch will undergo lab validation to confirm that the device can accurately track vital signs and blood loss indicators. Researchers will then build and refine a machine learning model using the data collected to identify early warning patterns. Finally, the device will be tested on patients in an operating room setting, particularly those at high risk for bleeding during or after surgery.

If successful, the technology could transform trauma care by providing a reliable, non-invasive, and comprehensive monitoring system capable of detecting hemorrhage at its earliest stages. By improving the speed and accuracy of medical interventions in the operating room and across care settings, this technology has the potential to save lives and advance emergency and trauma medicine.

Click here to learn more.

 

Venugopalan Named SPIE Fellow

By Lori Brandt, UC Irvine Samueli School of Engineering

Feb. 26, 2026 –SPIE, the international society for optics and photonics, has recognized Vasan Venugopalan, as one of 40 new fellows in 2026. Venugopalan is chair and professor of chemical and biomolecular engineering at UC Irvine. SPIE fellows are selected for making significant scientific and technical contributions in the multidisciplinary fields of optics, photonics and imaging. Venugopalan has achieved pioneering innovations in three research areas of biophotonics: laser ablation of biological tissues, pulsed laser microbeam interactions with cells, and computational biophotonics and dissemination of open-source software.

He also has made exceptional contributions in developing and implementing novel and impactful educational programs to support multidisciplinary training of students, researchers and industrial professionals in the area of biophotonics. His contributions have had tangible benefits for both UCI Ph.D. students across campus — impacting the Schools of Engineering, Physical Sciences, Biological Sciences and Medicine — as well as a larger population of academic and industrial researchers nationally and internationally.

Venugopalan’s efforts have resulted in the development of five extramurally funded ($6.5 million in total) multidisciplinary educational initiatives, each utilizing mixed methods, for intensive research education and training, coupled with professional development and technical and career mentorship. Examples include an NSF Integrated Graduate Education, Research and Training (IGERT) program, several NIH short courses and training programs in computational and biophotonics, and a UC/HBCU program for multidisciplinary research experience for undergraduate students.

“I’m tremendously honored to be recognized in this way and join a group of colleagues whose contributions and accomplishments I deeply respect,” said Venugopalan. His election was recognized in January at the Annual Fellows Luncheon at SPIE’s Photonics West Conference, the world’s largest conference in the field of optics and photonics.

Since SPIE’s inception in 1955, more than 1,800 SPIE members have become fellows.

Click here or visit https://bit.ly/vasan-named-spie to read full article on the UC Irvine Samueli School of Engineering website.

 

Can Wearable Tech Finally Get Blood Pressure Right?

– Jill Kato/UC Irvine Beall Applied Innovation

Forget the cuff. Vena Vitals’ sticker-like sensor aims to deliver ICU-level data without ever breaking the skin.

Feb. 19, 2026 – Blood pressure is one of the most important measurements in healthcare. Yet how we track it hasn’t changed much in more than a century.

The standard cuff with the squeeze, wait, release, gives a brief snapshot of a vital sign that has the potential to fluctuate with each passing beat. At the other extreme is the arterial line, a catheter inserted directly into an artery, delivering a continuous stream of data but with the downsides of cost, risk and invasive discomfort.

This binary choice has frustrated clinicians for decades. But a fast-rising startup out of UC Irvine may have uncovered a third way: a soft, skin-like sensor that adheres like a Band-Aid and captures blood pressure continuously, beat by beat. It works without punctures, cuffs, or bulky machines.

Founded in 2019, Vena Vitals is betting that its flexible “blood pressure sticker” can close one of the most persistent gaps in patient monitoring. The unobtrusive small device could replace hardware found in all intensive care units. The tech has already been tested on more than 600 patients in operating rooms across the country and is now moving toward FDA clearance for hospital use.

“This is a massive unmet need in healthcare,” Vena Vitals CEO Ray Liu says. “Our blood pressures are constantly changing, but we only get snapshots in time using uncomfortable cuff compressions, or we need risky invasive procedures to track real-time changes”

A New Pulse on Patient Monitoring

The journey to rethink how we track blood pressure began at UC Irvine, where Michelle Khine, a professor in the Department of Biomedical Engineering, first developed the underlying technology. It emerged from her lab’s research into soft, stretchable electronics. The material can stretch like skin while capturing highly sensitive data.

Liu first met Khine more than two decades ago as lab mates in grad school at UC Berkeley. There, they worked on numerous biomedical sensing applications, before their paths split, with Liu heading into industry and Khine pursuing academia. When the idea of reuniting on this venture appeared, neither could pass on the opportunity to tackle such an important unmet need.

Khine contributed the core material science innovation. Liu brought his experience from both large medtech companies and startup digital health exits. And together with Josh Kim, who developed the technology for his PhD and was the lead author on the seminal papers, the three completed the founding team.

Vena Vital’s device works by sensing the tiny changes in pressure on the skin caused by blood pulsing through the arteries. As each beat compresses the sensor, it produces a signal. If blood pressure rises, the signal intensifies. If it falls, the signal dampens. Proprietary algorithms interpret this data in real time.

Vena Vitals began focusing on surgical settings, where continuous blood pressure is essential. In clinical trials, their device was placed on the foot (a location that is out of the surgical field but still over a pulse location) and transmitted data via Bluetooth to a tablet. The results were striking. Side-by-side with arterial lines, the gold standard in the industry, the Vena Vitals device matched rapid blood pressure changes almost perfectly.

Anesthesiologists took notice and saw the potential. “They told us this could really change how they manage patients,” says Liu. “Especially since arterial lines are invasive, introduce patient risk, and have unpredictable procedure times. Sometimes it takes 10 minutes to place one—sometimes it takes 40. You don’t know how long until you try.”

The stakes in the operating room are high. Surgeons, nurses, and techs may all be waiting on that line before they can begin. If a noninvasive wearable can offer the same information with none of the drama, it’s not just a win for the patient, it’s a win for the entire surgical team.

From the OR to Your Bedroom

While Vena Vitals’ initial focus is inside the hospital, its ambitions extend beyond the operating room to the bedroom, where undiagnosed blood pressure-related conditions can go unnoticed.

Sleep apnea affects more than a billion people worldwide, yet most people don’t know they have it. The condition causes the body to stop breathing temporarily during sleep, triggering spikes in blood pressure as the body scrambles to recover lost oxygen. Over time, these repeated surges can put enormous strain on the heart, brain, and kidneys.

Vena Vitals’ device can detect those surges in exquisite detail. “We’re the first and only technology that can quantify the magnitude of blood pressure spikes immediately after apneic events,” says Liu. “That gives doctors a whole new way to assess how severe the condition really is.”

This could have major implications for treatment. Currently, the standard for diagnosing sleep apnea is the apnea-hypopnea index (AHI), which counts how many times you stop breathing per hour. But the AHI doesn’t provide the full view of the physiological impact of those events.

For example, a patient might stop breathing 12 times an hour—a case that would normally be labeled mild sleep apnea—but still experience intense blood pressure surges during each event. That kind of spike puts significant strain on the cardiovascular system. Another patient might stop breathing 70 times an hour, which would be diagnosed as severe, but only show mild pressure changes. In other words, what matters isn’t just how often the airway closes, it’s also how intensely the body responds. It’s hypothesized that repeated surges in blood pressure, especially at night, can increase the risk of heart attack, stroke and long-term damage. By including the intensity of these surges, rather than just counting how many times someone stops breathing, clinicians get a more accurate picture of cardiovascular risk.

“This gives us a much more nuanced view,” says Liu. “And in some cases, it can change how doctors decide to treat the patient.”

The long-term vision is for Vena Vitals’ sensors to be part of a comprehensive sleep monitoring system. It could also be integrated into consumer products.

“Consumers want more than sleep quality scores,” says Liu. “They want meaningful health data. And for people with chronic conditions, this kind of information could be game-changing.”

Geared for Impact

Vena Vitals is part of a wave of research-based ventures to take shape within UC Irvine’s innovation community. The company’s ties to the University run deep. It has space at the Cove at UCI and at University Lab Partners (ULP), an independent, nonprofit wet lab incubator located at UC Irvine Research Park. And of the company’s 14 employees, nine are UC Irvine alumni, including five Ph.D.s.

“The university has been foundational for us,” says Liu. “Not just for the technology, but for talent, infrastructure, clinical partnerships, everything.” That support included a Proof of Product (PoP) grant from Beall Applied Innovation, which helped the team conducted early market research and customer discovery, including interviews with about 30 anesthesiologists. The insights shaped both the product’s initial features and the clinical markets the company would pursue first. While the team had always envisioned consumer applications, the interviews reinforced the need to first stay clinically grounded.

“There’s a lot of noise in the wearable space,” says Liu. “But we’ve always been about clinical impact. We didn’t want this to be another gadget you wear. We wanted it to be something that delivers true medical outcomes.”

To get there, the company has secured a mix of venture funding and federal grants, with additional support from accelerators including Y Combinator, MedTech Innovator, and EvoNexus. FDA clearance is anticipated soon this year, which would open the door for the device’s use in hospitals.

Beyond that, the company is already planning for expansion—first into home sleep monitoring, then potentially into chronic disease management and remote patient care.

There’s no shortage of ambition, but Liu remains pragmatic. “We know we’re early,” he says. “But we also know what this could become.”

In a healthcare system built around snapshots, Vena Vitals is offering something rare: continuous insight without added discomfort. It’s a reminder that innovation doesn’t always mean doing more, sometimes it means finding a more elegant solution.

Learn more: https://www.venavitals.com

Click here to read full article on the UC Irvine Samueli School of Engineering website.

 

A laser focus on melanoma

Mihaela Balu and her team develop skin scanner that can better detect early signs of deadly cancer

When Mihaela Balu was interviewing for a postdoctoral position nearly two decades ago, she would describe the kind of training she was looking for, and nearly everyone she talked to nationwide said, “You should go to Beckman Laser Institute & Medical Clinic.” Fortunately for UC Irvine, she did.

Now an associate professor of dermatology and biomedical engineering, Balu and her team have developed a device that uses a low-power infrared laser to scan beneath the skin surface at a cellular level. The goal is to better detect early signs of melanoma – without biopsy – and to monitor the effectiveness of skin treatments. Balu has received several National Institutes of Health grants as well as funding from the Department of Defense: “They have soldiers in the field exposed to sun,” she notes.

With the device now in clinical trials, Balu says that none of this could have happened without federal support. “Those grants give us the ability to attract the best talent, and it’s important to have talented, passionate, dedicated people driving the research,” she says.

The competition for top-quality researchers is fierce, as private industry can offer better compensation. “I’m very fortunate to work with an exceptional team,” Balu says. “Within our larger group, we have a core set of people whose expertise is essential to our long-term success. It’s important to retain that core. We don’t want to hire talented people for a few years, lose funding and be forced to rebuild. Our goal is to maintain a stable foundation.”

Balu, a physicist and engineer by training, leads a team that includes two other physicists, a biologist, a chemist and a biomedical engineer. This broad range of skills is powerful in a setting where research shares the clinical space, something she notes is extremely rare.

“It allows us to track the performance of the devices we build, evaluate their limitations and get them back to the lab for design improvements,” she says.

The device – known as the fast, large-area, multiphoton exoscope – is wheeled into a clinical research room and connected to a small metal ring taped to a patient’s skin to ensure stability. A laser is used to excite molecules, allowing the FLAME to form detailed images of the cells and fibers underneath.

“The scan takes about 10 to 15 minutes right now, but the team is striving to shorten it to 5,” Balu says. “We don’t have technicians running studies; we run the devices on patients ourselves. It’s the only way to understand what needs to be improved.”

The goal? Being able to diagnose skin conditions without cutting and to monitor the success of various therapies, specifically immunotherapies for metastatic melanoma.

“We’re tracking the response at a cellular level to see when treatment is working or not,” Balu says. “That allows us to give feedback so therapies can be tailored to each individual.”

This means that patients make fewer trips to the doctor and get earlier detection and more specific treatment plans.

This year, Balu’s team is moving the device into new space on the recently completed UCI Health — Irvine campus.

“When I first started bringing complex technology like this into the clinic, we were squeezed into a storage room,” she says. “And now we’ll have two research rooms in the new building. That’s success for me.”

It’s this federally funded research and much more like it that keep UC Irvine moving forward and advancing its status. The campus has been ranked as one of the top 10 public universities in the country for more than a decade.

“I feel fortunate to have the opportunity to build my work and my career here,” Balu says. “I love the multidisciplinary culture and collaborative environment.”

Click here or visit https://bit.ly/balu-laser-focus to read full UC Irvine News article.

Click here or visit https://bit.ly/balu-laser-focus-video to watch video on the ucirvine YouTube channel.

Commercialization in Biophotonics: A conversation with David Cuccia and Amaan Mazhar about Modulim

Biophotonics Discovery: The Podcast

In this episode of our commercialization series, Darren and Gwen sit down with David Cuccia (President & CTO) and Amaan Mazhar (CEO) of Modulim, a biophotonics startup developing commercial applications of Spatial Frequency Domain Imaging (SFDI).

David and Amaan share their journey from graduate school at UC Irvine’s Beckman Laser Institute to building a medtech company. The conversation covers practical lessons about FDA regulatory pathways, the importance of quality systems, and how they’re addressing diabetic complications and amputations through tissue oxygenation measurements. They also share valuable insights about finding the right early adopter customers, adapting product form factors based on clinical feedback, and understanding that in medtech, you have multiple “customers”—from the FDA to insurance companies to physicians.

Whether you’re a researcher considering commercialization or simply curious about the path from lab to market, this episode offers an honest, detailed look at building a biophotonics startup.

Click here or visit https://bit.ly/biophotonicspod to listen to the “Biophotonics Discovery: The Podcast” episode.

Howard Lee selected as Moore Experimental Physics Investigator to Develop Revolutionary Nanoscale Electron Accelerator

Professor Howard Lee in the UC Irvine Department of Physics & Astronomy has been named a 2025 Experimental Physics Investigator by the Gordon and Betty Moore Foundation. The funding will support Lee in advancing groundbreaking research in nanoscale electron acceleration technology. Lee is developing the world’s first nanoscale electron accelerator by merging advanced nano-optical materials and nanostructures with laser wakefield acceleration. Unlike traditional accelerators such as the Large Hadron Collider that require extensive long well-defined channels, Lee’s apparatus uses nanoscale solid-state materials and high-power ultrafast lasers to accelerate electrons and generate X-rays.

“This award is significant since it allows me to pursue an entirely new research direction not previously explored,” Lee said. “Given the current funding climate, the opportunity to support research with bold new ideas is truly game-changing for my group, allowing us to further advance optical science and technology. I am deeply grateful to the Moore Foundation for their generous support.” Lee’s work could enable new medical therapies, including laser wakefield accelerator optical fiber endoscope probes and free electron laser devices for next-generation biomedical and imaging technologies. When integrated into optical fibers, these nanoscale accelerators could open transformative biomedical applications, including advanced cancer treatments.

Click here or visit https://heyzine.com/flip-book/2025SoPS#page/1 to read the full article in the 2025 UC Irvine School of Physical Sciences Deans Report.

2025 NSF Graduate Research Fellows

Eight students from the UC Irvine School of Physical Sciences received the prestigious 2025 National Science Foundation Graduate Research Fellowship (NSF GRFP) award. The fellowship is a five-year program that provides full financial support for three years, and it recognizes outstanding students pursuing research in STEM graduate programs.

“Not only do they pursue research in innovative and impactful fields, but they also perform a broad range of mentorship and training efforts aimed at lifting up those around them. When the nation funds these students, they are investing in the hundreds of other people that these students engage with as well.”
– Franklin Dollar, Associate Dean of Graduate Studies and professor in the UC Irvine Department of Physics & Astronomy

2025 UC IRVINE NSF GRFP RECIPIENTS

Massee Akbar – Physics & Astronomy

Massee Akbar graduated with his bachelor’s in physics from the UC Irvine Department of Physics & Astronomy this June and is beginning a Ph.D. this fall in the lab of Professor Howard Lee. With NSF support, Akbar is developing next-generation nanophotonic optical fibers—microscopes as thin as a human hair—by 3D-printing patterns onto fiber tips to control light without bulky lenses. The technology could one day make minimally invasive medical imaging possible.

Click here or visit https://heyzine.com/flip-book/2025SoPS#page/1 to read the full article in the 2025 UC Irvine School of Physical Sciences Deans Report.

UCI Health celebrates more than 215 Physicians of Excellence

Leaders in their specialty chosen by the Orange County Medical Association; more than any other OC health system

Orange, Calif. — More than 215 UCI Health doctors have been recognized as 2026 Physicians of Excellence by the Orange County Medical Association (OCMA), more than any other health system in the region.

OCMA’s Physician of Excellence program, now in its 22nd year, honors physicians in Orange County who have exhibited the skills, training and commitment to their patients and the community to stand above their peers as physicians of excellence.

The complete list, published in the January 2026 issue of Orange Coast Magazine, includes nearly 700 Orange County physicians across about 75 clinical specialties.

OCMA is regarded as having a fair and unbiased process for selecting Physicians of Excellence awardees. To be eligible for recognition, physicians are required to:

  • Be certified by a member board within the American Board of Medical Specialties, the American Board of Osteopathic Medical Specialties or an equivalent board recognized by the Medical Board of California or the Osteopathic Medical Board of California
  • Be in good standing with the Medical Board of California or Osteopathic Medical Board of California
  • Have maintained their primary practice in Orange County for the last five years
  • Have practiced within their specialty for the last five years

Doctors also are required to demonstrate achievements in at least two of the following criteria: physician leadership; teaching/mentoring; medical research/scientific advances; humanitarian service and unique contributions in community service.

UCI Health is proud to recognize our more than 215 UCI Health doctors named 2026 Physicians of Excellence. The compassionate, expert care they provide helps us deliver on our promise of a healthier tomorrow for our patients and our community as a whole.

2026 UCI Health Physicians of Excellence

Allergy
Donald S. Levy, MD

Anesthesiology
Kyle Ahn, MD
Melissa Chang, MD
Robert R. Field, MD
Kimberly M. Gimenez, MD
Anna L. Harris, MD
Richard J. Kelly, MD
Debra E. Morrison, MD
Ariana M. Nelson, MD
Kyle Parades, MD
Lynnus Peng, MD
Ramin Rahimian, MD
Anil Tiwari, MD
Trung Vu, MD
Gregory Yoshikawa, MD

Cardiovascular disease
Ailin Barseghian El-Farra, MD
Roxana Ghashghaei, MD
Jin Kyung Kim, MD, PhD
Ali Naqvi, MD
Pranav M. Patel, MD

Dermatology
Linda T. Doan, MD
Kristen M. Kelly, MD
Bonnie A. Lee, MD
Patrick K. Lee, MD
Natasha Mesinkovska, MD
Melissa L. Shive, MD
Janellen Smith, MD

Diagnostic radiology
Arash Anavim, MD
Joseph E. Burns, MD
Hyung Won Choi, MD
Maryam Golshan-Momeni, MD
Mohammad Helmy, MD
Roozbeh Houshyar, MD
Rony Kampalath, MD
Edward, Kuoy, MD
Irene S. Tsai, MD
Marisa Tseng, MD
Vahid Yaghmai, MD
Jennifer J. Young, MD

Emergency medicine
Patrick Aguilera, MD
Carrie Chandwani, MD
Heesun Choi, DO
Timothy Korber, MD
Mark I. Langdorf, MD
Megan Boysen Osborn, MD
Ronald J. Rivera, MD
Lindsay C. Spiegelman, MD
Alisa V. Wray, MD

Facial plastic & reconstructive surgery
Brian J.F. Wong, MD

Family medicine
Tan Q. Nguyen, MD
Andrew S. Nobe, MD
Baotran N. Vo, MD

Gastroenterology
C. Gregory Albers, MD
Ke-Qin Hu, MD
John G. Lee, MD
Christina Ling, MD
Nimisha K. Parekh, MD
Sandra Sunhee Park, MD
Jason B. Samarasena, MD

Geriatric medicine
Elham Arghami, MD
Lisa M. Gibbs, MD
Sonia R. Sehgal, MD
Steven P. Tam, MD

Gynecologic oncology
Krishnansu Tewari, MD
Jill Tseng, MD

Hematology-oncology
Elizabeth A. Brém, MD
Stefan O. Ciurea, MD
Deepa Jeyakumar, MD
Edward L. Nelson, MD
Zahra Pakbaz, MD
Lauren Pinter-Brown, MD
Richard A. Van Etten, MD, PhD

Hospice/palliative care
Shiho Ito, MD

Internal Medicine
Alpesh Amin, MD, MBA
Emilie L. Chow, MD
Sonali Iyer, MD
Bavani Nadeswaran, MD
Hoang Anh Nguyen, MD
Maryam Rahimi, MD
Virgil S. Raymundo, MD
Bobby Sasson, MD
Interventional radiology
Nadine Abi-Jaoudeh, MD
Dayantha M. Fernando, MDMaternal-fetal medicine
Judith H. Chung, MD, PhD
Afshan Hameed, MD
Tamera J. Hatfield, MD, PhD
Jennifer A. Jolley, MD
Carol Major, MD
Manuel Porto, MD
Jonathan G. Steller, MD

Medical oncology
Farshid Dayyani, MD, PhD
Nataliya Mar, MD
Arash Rezazadeh Kalebasty, MD
Jason A. Zell, DO

Neonatal-perinatal medicine
Muhammad Aslam, MD
Fayez Bany-Mohammed, MD
Rebecca J. Coleman, MD
Cherry Uy, MD

Neurodevelopmental disorders
Peter Chung, MD
Thusa Sabapathy, MD

Neurology
Yama Akbari, MD, PhD
Sanaz Attaripour Isfahani, MD
Mark J. Fisher, MD
Namita A. Goyal, MD
Xiao-Tang Kong, MD, PhD
Lilit Mnatsakanyan, MD
Tahseen Mozaffar, MD
Mona Sazgar, MD

Nephrology
Anthony Ferrey, MD
Ramy Hanna, MD
Wei Ling Lau, MD
Uttam Reddy, MD
Ekamol Tantisattamo, MD

Neurosurgery
Jefferson Chen, MD, PhD
Kiarash Golshani, MD
Frank P.K. Hsu, MD, PhD
Mark E. Linskey, MD
Michael Y. Oh, MD
Michelle Paff, MD
Sumeet Vadera, MD

Nuclear medicine
Sindu Alexander, MD

Obstetrics & gynecology
Donna Baick, MD
Jennifer Butler, MD
Nkiruka Chuba, MD
Tabetha R. Harken, MD
Christine Kim, MD
Michael L Krychman, MD
Jasmine Patel, MD
Rachel Perry, MD
Rebecca M. Sauer, MD

Occupational health
Scott E. Hardy, MD

Ophthalmology
Andrew W. Browne, MD
Robert W. Crow, MD
Lilangi S. Ediriwickrema, MD
Marjan Farid, MD
Sumit (Sam) Garg, MD
Charlotte Gore, MD
Sanjay Kedhar, MD
Baruch D. Kuppermann, MD, PhD
Ken Y. Lin, MD
Stephanie Y. Lu, MD
Mitul C. Mehta, MD
Sameh Mosaed, MD
Jeremiah P. Tao, MD
Matthew W. Wade, MD

Orthopaedic surgery
Nitin N. Bhatia, MD
Andrew R. Hsu, MD
Yu-Po Lee, MD
John A. Scolaro, MD
Russell N. Stitzlein, MD
Dean Wang, MD 

Otolaryngology/Head & Neck Surgery
William B. Armstrong, MD
Naveen D. Bhandarkar, MD
Hamid R. Djalilian, MD
Edward C. Kuan, MD
Sepehr Oliaei, MD
Tjoson Tjoa, MD

Pathology
Cassiana E. Bittencourt, MD
Julio A. Ibarra, MD

Pediatrics
Behnoosh Afghani, MD
Amy Cheng, MD
Melitza Cobham-Browne, MD
Elsie Rosso Hidalgo, MD
Leticia C. Oliveros, MD
Candice E. Taylor, MD

Pediatric medical genetics
June-Anne Gold, MD
Virginia Kimonis, MD

Pediatric radiology
Liliane Gibbs, MD

Pediatric urology
Kai-wen Chuang, MD
Heidi A. Stephany, MD
Elias Wehbi, MD

Physical medicine & rehabilitation
Danielle Perret Karimi, MD
David W. Lee, MD

Plastic surgery
Gregory R.D. Evans, MD
Daniel Jaffurs, MD

Psychiatry
Rimal B. Bera, MD
John Luo, MD
Robert McCarron, DO

Pulmonary disease
Richard A. Lee, MD

Rheumatology
Sheetal Desai, MD
Alan Schenk, MD

Surgery
Cristobal Barrios Jr., MD
Joseph C. Carmichael, MD
Shaun Daly, MD
Marcelo W. Hinojosa, MD
David K. Imagawa, MD, PhD
Zelijka Jutric, MD
Kari Kansal, MD
Karen T. Lane, MD
Melissa L. Mao, MD
Jeffry T. Nahmias, MD
Ninh T. Nguyen, MD
Brian R. Smith, MD

Thoracic surgery
Ali Mahtabifard, MD

Transfusion medicine
Minh-Ha Tran, DO

Urogynecology
Taylor Brueseke, MD
Felicia L. Lane, MD
Dena E. Moskowitz, MD

Urology
Ralph V. Clayman, MD
Joel Gelman, MD
Gamal M. Ghoniem, MD
Greg E. Gin, MD
Pengbo, Jiang, MD
Mark L. Jordan, MD
Jaime Landman, MD
Ross Moskowitz, MD
Roshan M. Patel, MD
M. Leon Seard II, MD
Edward Uchio, MD
Faysal A. Yafi, MD

Vascular surgery
Anthony H. Chau, MD
Samuel L. Chen, MD
Roy M. Fujitani, MD
Nii-Kabu Kabutey, MD
Isabella J. Kuo, MD

About UCI Health
UCI Health, one of California’s largest academic health systems, is the clinical enterprise of the University of California, Irvine. The 1,461-bed system comprises its main campus UCI Health — Orange, its flagship hospital, the UCI Health — Irvine acute care hospital and medical campus, four hospitals and affiliated physicians of the UCI Health Community Network in Orange and Los Angeles counties and a network of ambulatory care centers across the region. UCI Health — Orange provides tertiary and quaternary care and is home to the only Orange County-based National Cancer Institute-designated comprehensive cancer center, high-risk perinatal/neonatal program and American College of Surgeons-verified Level I adult and Level II pediatric trauma center, gold level 1 geriatric emergency department and regional burn center. Powered by UC Irvine, UCI Health serves 5.6 million people in Orange County, western Riverside County and southeast Los Angeles County. Follow us on Facebook, Instagram, LinkedIn and X (formerly Twitter).

Click here to read full article on UCI Health News.

Institute Investigators Receive NHLBI Catalyze Program Grant to Develop Maternal Health Monitoring Technology

UC Irvine Beckman Laser Institute & Medical Clinic researchers Drs. Bernard Choi and Michelle Khine have been awarded a $1.2 million grant from the National Heart, Lung, and Blood Institute (NHLBI) for the project, “Maternal Obstetric Monitoring System (MOMS): a Postpartum Hemorrhage (PPH) Wearable Monitor.”  This award brings the researchers into the NHLBI’s Catalyze Program, a comprehensive translational research support mechanism that provides funding, project management, technical services, and commercialization guidance designed to accelerate the translation of new therapies, devices, and diagnostics to market.

The project aims to develop MOMS, a technology designed to improve early detection of postpartum hemorrhage (PPH), a leading cause of maternal death. By continuously monitoring vital signs, measuring high-quality physiological waveforms, and performing advanced analysis of the measurements, MOMS seeks to identify significant blood loss in new mothers more effectively than current methods, potentially saving lives and improving maternal health outcomes.

The multidisciplinary team – comprising experts in biomedical engineering, obstetrics & gynecology, sociology, and data science – will create a miniaturized, wearable device integrated with multiple sensors.  The device will simultaneously measure continuous blood pressure, heart rate, cardiac output, stroke volume, blood flow, hemoglobin oxygen saturation, and oxygen utilization to facilitate early detection of hypovolemia, or insufficient blood circulation.

The project will deliver a uniquely comprehensive hemodynamic and hemorrhage monitor specifically designed for PPH detection. The team will first finalize their alpha prototype and conduct preliminary validation. The next phase involves refining the technology to create a low-profile, user-friendly beta prototype based on end-user requirements and validated through testing on a diverse population. Data collected will inform predictive algorithm development, culminating in a pilot study with pregnant women during and after delivery.

Upon successful completion, the validated MOMS sensor technology will be ready for both hospital and ambulatory monitoring use during delivery and postpartum care.  MOMS will provide more accurate, precise and robust early indicators of PPH than commercially available technologies, ultimately improving maternal survival rates.

NHLBI’s Catalyze Program enables and expedites the translation of basic science discoveries into new treatments, devices, and diagnostics for patients with heart, lung, blood, and sleep disorders (HLBS).  The program advances potential new medical products through development to the preclinical testing stage by providing research funding, mentoring, advisory services, technology development guidance, regulatory affairs support, commercialization assistance, skills development and education.

About Catalyze

Catalyze’s mission is to provide comprehensive support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates cleared for human testing, while developing a translational research workforce fluent in product development and entrepreneurship.  The organization’s strategies include, funding for HLBS-related therapies, and diagnostics across the translational continuum; supporting scientists in setting achievable milestones that advance projects along the research pathway, educating investigators in translation, marketing, and product commercialization; anticipating researcher needs so they can focus on science rather than project administration; and pivoting funding and support quickly based on evolving project and scientific requirements.

Click here to learn more about Catalyze.

The research described above is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

 

Dima Fishman, Eric Potma and Aleks Noskov receive the Beall Innovation Award in the Physical Sciences

The award will support research into silicon-based LEDs.

By Lucas Van Wyk Joel | UC Irvine School of Physical Sciences

Adjunct Professor Dmitry Fishman, Professor Eric Potma, and Dr. Aleks Noskov of the UC Irvine Department of Chemistry were awarded 11th annual Beall Innovation Award in the Physical Sciences. The team received the award after presenting a winning talk titled “Unlocking Light in Silicon: First Ultrabroadband Light-emitting Diode Made from Silicon,” which they gave during the School of Physical Science’s Shark Tank event on Monday, November 17. During the presentation, the team outlined how silicon, despite being the backbone of modern electronics, remains fundamentally limited by its inability to efficiently emit light. This long-standing constraint has impeded progress toward low-cost, bright, silicon-based light sources and, more importantly, fully integrated silicon photonics – a technology that uses light to transfer data on computer microchips. “Overcoming fundamental barriers in current semiconductor technologies, without abandoning the existing silicon manufacturing infrastructure, requires a new way of controlling light–matter interactions,” said Fishman. “Building on a recent discovery of a new quantum photonic phenomenon, photonic Heisenberg matter, we focus not on modifying the material, but on engineering the photonic state. In other words, light itself.” It’s work that could lead to completely new technologies. “Leveraging this newly discovered quantum photonic phenomenon, our project aims to deliver the first energy-efficient, electrically driven, all-silicon light-emitting diode,” Potma said. “If successful, this platform could redefine the landscape of silicon photonics, opening opportunities once considered unattainable and accelerating innovation across the entire field of electronics that interact in some way with light.”

Click here to read full article on the UC Irvine School of Physical Sciences website.